Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article

The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap

Henry Szechtman, Brian H. Harvey, Erik Z. Woody and Kurt Leroy Hoffman
Jeffrey M. Witkin, ASSOCIATE EDITOR
Pharmacological Reviews January 2020, 72 (1) 80-151; DOI: https://doi.org/10.1124/pr.119.017772
Henry Szechtman
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada (H.S.); SAMRC Unit on Risk Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, and Center of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University (Potchefstroom Campus), Potchefstroom, South Africa (B.H.H.); Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada (E.Z.W.); and Centro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico (K.L.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian H. Harvey
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada (H.S.); SAMRC Unit on Risk Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, and Center of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University (Potchefstroom Campus), Potchefstroom, South Africa (B.H.H.); Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada (E.Z.W.); and Centro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico (K.L.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Z. Woody
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada (H.S.); SAMRC Unit on Risk Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, and Center of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University (Potchefstroom Campus), Potchefstroom, South Africa (B.H.H.); Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada (E.Z.W.); and Centro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico (K.L.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt Leroy Hoffman
Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada (H.S.); SAMRC Unit on Risk Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, and Center of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University (Potchefstroom Campus), Potchefstroom, South Africa (B.H.H.); Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada (E.Z.W.); and Centro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico (K.L.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey M. Witkin
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 72 no. 1 80-151
DOI 
https://doi.org/10.1124/pr.119.017772
PubMed 
31826934

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0031-6997
Online ISSN 
1521-0081
History 
  • Published online December 11, 2019.

Copyright & Usage 
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Henry Szechtman,
  2. Brian H. Harvey,
  3. Erik Z. Woody, and
  4. Kurt Leroy Hoffman
  1. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada (H.S.); SAMRC Unit on Risk Resilience in Mental Disorders, Department of Psychiatry, University of Cape Town, and Center of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University (Potchefstroom Campus), Potchefstroom, South Africa (B.H.H.); Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada (E.Z.W.); and Centro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico (K.L.H.)
  1. Jeffrey M. Witkin, ASSOCIATE EDITOR
  1. Address correspondence to:
    Dr. Henry Szechtman, Department of Psychiatry and Behavioural Neurosciences, McMaster University, MUMC, 4N82, 1280 Main St. West, Hamilton, ON L8S 4K1, Canada. E-mail: szechtma{at}mcmaster.ca
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: December 2019 to March 2021

AbstractFullPdf
Dec 2019101516166
Jan 2020497142172
Feb 202039213040
Mar 20202373118
Apr 20203111919
May 20202351926
Jun 20202191119
Jul 20201071014
Aug 2020163511
Sep 20201691825
Oct 20201781622
Nov 20202041215
Dec 2020959356
Jan 20211916577
Feb 202129250145
Mar 202177319

PreviousNext
Back to top

In this issue

Pharmacological Reviews: 72 (1)
Pharmacological Reviews
Vol. 72, Issue 1
1 Jan 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

Psychopharmacology of OCD: A Preclinical Roadmap

Henry Szechtman, Brian H. Harvey, Erik Z. Woody and Kurt Leroy Hoffman
Pharmacological Reviews January 1, 2020, 72 (1) 80-151; DOI: https://doi.org/10.1124/pr.119.017772

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Review ArticleReview Article

Psychopharmacology of OCD: A Preclinical Roadmap

Henry Szechtman, Brian H. Harvey, Erik Z. Woody and Kurt Leroy Hoffman
Pharmacological Reviews January 1, 2020, 72 (1) 80-151; DOI: https://doi.org/10.1124/pr.119.017772
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Overview
    • II. Currently Accepted Practice and Understanding of Obsessive-Compulsive Disorder
    • III. Current Research on the Neurobiology of Obsessive-Compulsive Disorder
    • IV. Toward a New Perspective on Preclinical Research
    • V. Toward a New Perspective on Psychopharmacological Research on Obsessive-Compulsive Disorder
    • VI. Summary and Conclusions
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Hydroxynorketamines Pharmacology
  • Sex-Based Pharmacology
  • Pharmacology of Polymyxins
Show more Review Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics